AzTrials
AzTrials

Respiratory Insufficiency Syndrome of NewbornNCT04075123

CPAP vs NIPPV: A COMPARATIVE EFFECTIVENESS RESEARCH

An observational study of Respiratory Insufficiency Syndrome of Newborn, run by Canadian Neonatal Network at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim: Investigators aim is to conduct two complementary and concurrent CER projects using a pragmatic clinical trial design and registry-based RWD to identify the optimal respiratory management practices for extremely preterm neonates and reduce the risk of BPD and SNI. Read more about this study

Who is it for?
Ages 23 to 28 weeks
What is being tested?
CPAP
How many people
1,829 participants
Where
1 siteCanada
Study dates
1 Oct 2019to 30 Dec 2022
How long will I take part?
12 Weeks
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 28 weeks
  • All sexes
  • No healthy volunteers
  • Child

Study population: Preterm neonates <29 weeks gestational age (including outborns) who have required mechanical ventilation at any time during their clinical course.

Who may be able to join

  • Preterm neonates <29 weeks gestational age
  • Receipt of mechanical ventilation

Who cannot join

  • Not received mechanical ventilation or active care
  • Congenital/genetic/chromosomal anomalies

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Mount Sinai Hospital

    Toronto, Ontario, M5G1X5

Other trials in Canada

About this study

Official title: Respiratory Management Of Extremely Preterm Neonates: Evidence Generation And Implementation By Comparative Effectiveness Research (CER) Using Real World Data (RWD) From A Practice-Based Research Network (PBRN)

Aim: Investigators aim is to conduct two complementary and concurrent CER projects using a pragmatic clinical trial design and registry-based RWD to identify the optimal respiratory management practices for extremely preterm neonates and reduce the risk of BPD and SNI.

Objectives: Two complementary objectives are proposed. Objective 1: To determine the efficacy and safety of "mandatory non-extubation" until 72 hours of postnatal age for preterm neonates born at 23 -25 weeks' GA who receive mechanical ventilation.

Objective 2: To determine whether optimal nasal continuous positive airway pressure post-extubation is as efficacious as nasal intermittent positive pressure ventilation in preterm neonates born at 23 -28 weeks' GA who have received mechanical ventilation.

Read the detailed description

Background and Importance: Preterm neonates <29 weeks' gestational age (GA) have a 10% risk of mortality, 15% risk of severe neurological injury (SNI) and 45% risk of bronchopulmonary dysplasia (BPD). Both SNI and BPD are associated with significant long-term impairment. Various management approaches to prevent these complications are adopted without rigorous evaluation because conducting large-scale randomized trials can be challenging. One area consistently associated with SNI and BPD is respiratory management of these neonates which is also the area lacking evidence-informed approach. Comparative effectiveness research (CER) of different management strategies using Real World Data (RWD) is suggested as an alternative to generate Real World Evidence (RWE). Hypotheses Evaluating Treatment Effectiveness (HETE) studies are a form of CER where two or more practices are compared to evaluate presence or absence of anticipated effect using specific hypothesis. In this proposal, investigators will study two specific respiratory management practices for preterm neonates <29 weeks' GA using this design under the auspices of our practice based research network of the Canadian Preterm Birth Network (CPTBN) which has extensive routine data collection for this population.

Aim: Investigators aim to conduct two complementary and concurrent CER projects using a pragmatic clinical trial design and registry-based RWD to identify the optimal respiratory management practices for extremely preterm neonates and reduce the risk of BPD and SNI.

Objectives: Two complementary objectives are proposed. Objective 1: To determine the efficacy and safety of "mandatory non-extubation" until 72 hours of postnatal age for preterm neonates born at 23 -25 weeks' GA who receive mechanical ventilation.

Objective 2: To determine whether optimal nasal continuous positive airway pressure post-extubation is as efficacious as nasal intermittent positive pressure ventilation in preterm neonates born at 23 -28 weeks' GA who have received mechanical ventilation.

Methods:

Approach: These two CER projects will compare respiratory management approaches at the unit-level allowing investigators to study all eligible preterm neonates admitted to participating units. Twenty units in Canada have agreed to participate in each project, and The units have participated in the conception of the study, standardizing two-arms of the protocol and agreed on the project-specific data requirements.

Duration: The study will run over 4 years. Sample size: Considering superiority approach investigators will study 800 neonates for project 1 (α=0.05, β=0.2, baseline rate 35-40% and 30% relative risk reduction).

If there was a true difference in risk of failure of 1% in CPAP group (30% vs 29%), then 1816 patients were required to be 80% sure that the upper limit of a one-sided 97.5% confidence interval (or equivalently a 95% two-sided confidence interval) would exclude a difference in favour of the NIPPV group of more than 5% for neonates of 23 -28 weeks' GA for project 2. (modification in Nov 2021, uploaded later)

Analyses: In order to generate information necessary for causal inference in a pragmatic experimental design, investigators will conduct three-pronged sensitivity analyses: logistic regression, propensity-score based analyses and instrumental variable analyses to confirm or refute our hypotheses and improve generalizability of results. Expertise: The research team includes the expertise of clinicians, researchers, epidemiologists, knowledge users, parents and statisticians.

Expected outcomes: Through use of RWD collected by the CPTBN and HETE design, the proposal will result in identifying a superior respiratory management strategy and reduced risk of mortality, SNI, and BPD for extremely preterm neonates.

Being tested
CPAP
Keywords
CPAP, NIPPV, INFANT, PREMATURE, RESPIRATORY MANAGEMENT, POST-ESTUBATION
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CPAPOther

    Also called NIPPV

    The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.

Study groups in NCT04075123
Study groupRoleWhat they receive
CPAP GROUPSuggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
Receives: Other: CPAP
NIPPV GROUPSuggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Failure on assigned NRS mode within 72 hours post-initial extubation

    • CPAP arm
    • Switch to any one of: NIPPV (including NIV-NAVA), or NIHFV
    • Escalation of CPAP PEEP >12 cmH2O
    • Intubation
    • NIPPV arm
    • Switch to any one of: NIHFV or NIV-NAVA (for centres that use unsynchronized NIPPV as their primary post-extubation mode)
    • Escalation of NIPPV beyond any one or more of the maximum allowable settings as described earlier
    • Switch to CPAP with PEEP > calculated MAP on NIPPV
    • Intubation

    Measured: 72 hours

Secondary outcomes (11)
  1. Failure on assigned NRS mode within 7 days post-initial extubation

    Measured: 7 days

  2. Need for intubation within 72 hours and 7 days post-initial extubation

    Measured: 72 hours and 7 days

  3. Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA

    Measured: 36 weeks post mestrual age

  4. Mortality before hospital discharge

    Measured: through study completion, an average of 14 weeks

  5. PMA when off positive pressure support

    Measured: through study completion, an average of 14 weeks

  6. Days of EMV (Post-initial extubation)

    Measured: through study completion, an average of 14 weeks

  7. Days of non-invasive respiratory support including high flow (Post-initial extubation)

    Measured: through study completion, an average of 14 weeks

  8. Days of any respiratory support (Post-initial extubation)

    Measured: through study completion, an average of 14 weeks

  9. Days of supplemental oxygen requirement (Post-initial extubation)

    Measured: through study completion, an average of 14 weeks

  10. Chronological age and post-menstrual age at time of full enteral feeds

    Measured: through study completion, an average of 14 weeks

  11. Air leak (Post-initial extubation)

    Measured: through study completion, an average of 14 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2019
  2. Study start1 Oct 2019
  3. Primary completion30 Dec 2021
  4. Study completion30 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,829 participants (actual)
Target duration
12 Weeks
IDs, dates and publications
ClinicalTrials.gov ID
NCT04075123
Sponsor's protocol ID
2019-01
Status last verified
Apr 2023
First submitted
27 Aug 2019
Last updated
26 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We do not have mechanisms to ask patients to allow data sharing.

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Insufficiency Syndrome of Newborn, run by Canadian Neonatal Network at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Failure on assigned NRS mode within 72 hours post-initial extubation (time frame: 72 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in